# Life360, Inc.: financial statements, quarterly

LIF · Nasdaq · CIK 1581760 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lif.md) · [Financials](/companies/lif/financials.md) · [Filings](/companies/lif/filings.md) · [Insiders](/companies/lif/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lif/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [78.6](/filings/0001581760-24-000104.md) | [87.0 d](/filings/0001581760-26-000016.md) | [78.2](/filings/0001581760-25-000106.md) | [84.9](/filings/0001581760-25-000180.md) | [92.9](/filings/0001581760-25-000224.md) | [116 d](/filings/0001581760-26-000016.md) | [104](/filings/0001581760-26-000078.md) | [115](/filings/0001581760-26-000141.md) | [124](/filings/0001581760-25-000224.md) | [146 d](/filings/0001581760-26-000016.md) | [143](/filings/0001581760-26-000078.md) | [159](/filings/0001581760-26-000141.md) |
| Cost of revenue | $m | [20.7](/filings/0001581760-24-000104.md) | [26.8 d](/filings/0001581760-26-000016.md) | [18.2](/filings/0001581760-25-000106.md) | [21.2](/filings/0001581760-25-000180.md) | [22.9](/filings/0001581760-25-000224.md) | [30.0 d](/filings/0001581760-26-000016.md) | [20.1](/filings/0001581760-26-000078.md) | [24.9](/filings/0001581760-26-000141.md) | [27.4](/filings/0001581760-25-000224.md) | [36.3 d](/filings/0001581760-26-000016.md) | [32.6](/filings/0001581760-26-000078.md) | [32.1](/filings/0001581760-26-000141.md) |
| Gross profit | $m | [57.9](/filings/0001581760-24-000104.md) | [60.1 d](/filings/0001581760-26-000016.md) | [60.0](/filings/0001581760-25-000106.md) | [63.6](/filings/0001581760-25-000180.md) | [70.0](/filings/0001581760-25-000224.md) | [85.5 d](/filings/0001581760-26-000016.md) | [83.5](/filings/0001581760-26-000078.md) | [90.5](/filings/0001581760-26-000141.md) | [97.1](/filings/0001581760-25-000224.md) | [110 d](/filings/0001581760-26-000016.md) | [111](/filings/0001581760-26-000078.md) | [127](/filings/0001581760-26-000141.md) |
| Research and development | $m | [24.6](/filings/0001581760-24-000104.md) | [26.0 d](/filings/0001581760-26-000016.md) | [27.3](/filings/0001581760-25-000106.md) | [27.0](/filings/0001581760-25-000180.md) | [29.0](/filings/0001581760-25-000224.md) | [29.8 d](/filings/0001581760-26-000016.md) | [30.4](/filings/0001581760-26-000078.md) | [32.3](/filings/0001581760-26-000141.md) | [32.4](/filings/0001581760-25-000224.md) | [33.3 d](/filings/0001581760-26-000016.md) | [39.3](/filings/0001581760-26-000078.md) | [47.4](/filings/0001581760-26-000141.md) |
| Operating income | $m | [(6.5)](/filings/0001581760-24-000104.md) | [(4.3) d](/filings/0001581760-26-000016.md) | [(6.4)](/filings/0001581760-25-000106.md) | [(2.4)](/filings/0001581760-25-000180.md) | [(5.0)](/filings/0001581760-25-000224.md) | [5.7 d](/filings/0001581760-26-000016.md) | [2.2](/filings/0001581760-26-000078.md) | [2.0](/filings/0001581760-26-000141.md) | [5.7](/filings/0001581760-25-000224.md) | [9.0 d](/filings/0001581760-26-000016.md) | [(8.1)](/filings/0001581760-26-000078.md) | [(0.1)](/filings/0001581760-26-000141.md) |
| Income tax | $m | [(0.2)](/filings/0001581760-24-000104.md) | [0.4 d](/filings/0001581760-26-000016.md) | [1.4](/filings/0001581760-25-000106.md) | [5.5](/filings/0001581760-25-000180.md) | [(4.7)](/filings/0001581760-25-000224.md) | [(2.2) d](/filings/0001581760-26-000016.md) | [(0.2)](/filings/0001581760-26-000078.md) | [(0.4)](/filings/0001581760-26-000141.md) | [0.4](/filings/0001581760-25-000224.md) | [(118) d](/filings/0001581760-26-000016.md) | [(11.7)](/filings/0001581760-26-000078.md) | [(4.0)](/filings/0001581760-26-000141.md) |
| Net income | $m | [(6.5)](/filings/0001581760-24-000104.md) | [(3.1) d](/filings/0001581760-26-000016.md) | [(9.8)](/filings/0001581760-25-000224.md) | [(11.0)](/filings/0001581760-25-000224.md) | [7.7](/filings/0001581760-25-000224.md) | [8.5 d](/filings/0001581760-26-000016.md) | [4.4](/filings/0001581760-26-000141.md) | [7.0](/filings/0001581760-26-000141.md) | [9.8](/filings/0001581760-25-000224.md) | [130 d](/filings/0001581760-26-000016.md) | [2.8](/filings/0001581760-26-000141.md) | [5.1](/filings/0001581760-26-000141.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001581760-24-000104.md) | not reported | [(0.14)](/filings/0001581760-25-000106.md) | [(0.15)](/filings/0001581760-25-000180.md) | [0.09](/filings/0001581760-25-000224.md) | not reported | [0.05](/filings/0001581760-26-000078.md) | [0.08](/filings/0001581760-26-000141.md) | [0.11](/filings/0001581760-25-000224.md) | not reported | [0.03](/filings/0001581760-26-000078.md) | [0.06](/filings/0001581760-26-000141.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0001581760-24-000104.md) | not reported | [(0.14)](/filings/0001581760-25-000106.md) | [(0.15)](/filings/0001581760-25-000180.md) | [0.10](/filings/0001581760-25-000224.md) | not reported | [0.06](/filings/0001581760-26-000078.md) | [0.09](/filings/0001581760-26-000141.md) | [0.13](/filings/0001581760-25-000224.md) | not reported | [0.03](/filings/0001581760-26-000078.md) | [0.06](/filings/0001581760-26-000141.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [61.8](/filings/0001581760-24-000104.md) | [69.0](/filings/0001581760-26-000016.md) | [73.4](/filings/0001581760-25-000106.md) | [161](/filings/0001581760-25-000180.md) | [159](/filings/0001581760-25-000224.md) | [159](/filings/0001581760-26-000016.md) | [169](/filings/0001581760-26-000078.md) | [433](/filings/0001581760-26-000141.md) | [456](/filings/0001581760-25-000224.md) | [494](/filings/0001581760-26-000141.md) | [351](/filings/0001581760-26-000078.md) | [267](/filings/0001581760-26-000141.md) |
| Current assets | $m | [125](/filings/0001581760-23-000124.md) | [131](/filings/0001581760-25-000008.md) | [131](/filings/0001581760-24-000031.md) | [218](/filings/0001581760-24-000080.md) | [235](/filings/0001581760-24-000104.md) | [241](/filings/0001581760-26-000016.md) | [250](/filings/0001581760-25-000106.md) | [521](/filings/0001581760-25-000180.md) | [557](/filings/0001581760-25-000224.md) | [606](/filings/0001581760-26-000141.md) | [590](/filings/0001581760-26-000078.md) | [599](/filings/0001581760-26-000141.md) |
| Total assets | $m | [316](/filings/0001581760-23-000124.md) | [322](/filings/0001581760-25-000008.md) | [319](/filings/0001581760-24-000031.md) | [406](/filings/0001581760-24-000080.md) | [427](/filings/0001581760-24-000104.md) | [442](/filings/0001581760-26-000016.md) | [455](/filings/0001581760-25-000106.md) | [754](/filings/0001581760-25-000180.md) | [787](/filings/0001581760-25-000224.md) | [960](/filings/0001581760-26-000141.md) | [1,041](/filings/0001581760-26-000078.md) | [1,052](/filings/0001581760-26-000141.md) |
| Current liabilities | $m | [72.7](/filings/0001581760-23-000124.md) | [70.8](/filings/0001581760-25-000008.md) | [74.0](/filings/0001581760-24-000031.md) | [77.6](/filings/0001581760-24-000080.md) | [85.3](/filings/0001581760-24-000104.md) | [77.3](/filings/0001581760-26-000016.md) | [74.0](/filings/0001581760-25-000106.md) | [73.0](/filings/0001581760-25-000180.md) | [81.9](/filings/0001581760-25-000224.md) | [96.8](/filings/0001581760-26-000141.md) | [110](/filings/0001581760-26-000078.md) | [107](/filings/0001581760-26-000141.md) |
| Total liabilities | $m | [76.1](/filings/0001581760-23-000124.md) | [74.7](/filings/0001581760-25-000008.md) | [78.9](/filings/0001581760-24-000031.md) | [79.2](/filings/0001581760-24-000080.md) | [87.7](/filings/0001581760-24-000104.md) | [83.0](/filings/0001581760-26-000016.md) | [79.1](/filings/0001581760-25-000106.md) | [387](/filings/0001581760-25-000180.md) | [396](/filings/0001581760-25-000224.md) | [412](/filings/0001581760-26-000141.md) | [443](/filings/0001581760-26-000078.md) | [438](/filings/0001581760-26-000141.md) |
| Long-term debt | $m | [4.5](/filings/0001581760-23-000124.md) | [4.5](/filings/0001581760-24-000006.md) | [5.2](/filings/0001581760-24-000031.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [240](/filings/0001581760-24-000104.md) | [247](/filings/0001581760-26-000016.md) | [240](/filings/0001581760-25-000224.md) | [327](/filings/0001581760-25-000224.md) | [340](/filings/0001581760-25-000224.md) | [359](/filings/0001581760-26-000141.md) | [376](/filings/0001581760-26-000141.md) | [367](/filings/0001581760-26-000141.md) | [391](/filings/0001581760-25-000224.md) | [548](/filings/0001581760-26-000141.md) | [598](/filings/0001581760-26-000141.md) | [613](/filings/0001581760-26-000141.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.1 d](/filings/0001581760-24-000104.md) | [9.0 d](/filings/0001581760-26-000016.md) | [10.7](/filings/0001581760-25-000106.md) | [3.3 d](/filings/0001581760-25-000180.md) | [6.3 d](/filings/0001581760-25-000224.md) | [12.3 d](/filings/0001581760-26-000016.md) | [12.1](/filings/0001581760-26-000078.md) | [13.3 d](/filings/0001581760-26-000141.md) | [26.4 d](/filings/0001581760-25-000224.md) | [36.8 d](/filings/0001581760-26-000016.md) | [17.2](/filings/0001581760-26-000078.md) | [23.8 d](/filings/0001581760-26-000141.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001581760-24-000104.md) | [0.5 d](/filings/0001581760-26-000016.md) | [0.0](/filings/0001581760-25-000106.md) | [0.1 d](/filings/0001581760-25-000180.md) | [0.0 d](/filings/0001581760-25-000224.md) | [1.1 d](/filings/0001581760-26-000016.md) | [0.1](/filings/0001581760-26-000078.md) | [0.6 d](/filings/0001581760-26-000141.md) | [0.8 d](/filings/0001581760-25-000224.md) | [0.2 d](/filings/0001581760-26-000016.md) | [0.0](/filings/0001581760-26-000078.md) | [0.0 d](/filings/0001581760-26-000141.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [62.2](/filings/0001581760-23-000124.md) | [65.6](/filings/0001581760-24-000031.md) | [66.5](/filings/0001581760-24-000080.md) | [67.1](/filings/0001581760-24-000104.md) | [68.5](/filings/0001581760-25-000106.md) | [70.8](/filings/0001581760-25-000180.md) | [82.1](/filings/0001581760-25-000224.md) | [83.4](/filings/0001581760-26-000078.md) | [84.5](/filings/0001581760-26-000141.md) | [85.8](/filings/0001581760-25-000224.md) | [85.7](/filings/0001581760-26-000078.md) | [85.6](/filings/0001581760-26-000141.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 81,480,369 at 2026-08-04, from the cover of the [10-Q filed 2026-08-10](/filings/0001581760-26-000141.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.